These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15883268)

  • 21. Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury.
    Fox RJ; Kivisakk P; Fisher E; Tucky B; Lee JC; Rudick RA; Ransohoff RM
    Mult Scler; 2008 Sep; 14(8):1036-43. PubMed ID: 18701575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Total brain T2-hyperintense lesion-volume and the axonal damage in the normal-appearing white matter of brainstem in early lapsing-remitting multiple sclerosis].
    Pascual-Lozano AM; Martínez-Bisbal MC; Boscá-Blasco I; Valero-Merino C; Coret-Ferrer F; Martí-Bonmatí L; Martínez-Granados B; Celda B; Casanova-Estruch B
    Rev Neurol; 2007 Oct 16-31; 45(8):468-73. PubMed ID: 17948212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis.
    Kantarci OH; Morales Y; Ziemer PA; Hebrink DD; Mahad DJ; Atkinson EJ; Achenbach SJ; De Andrade M; Mack M; Ransohoff RM; Lassmann H; Bruck W; Weinshenker BG; Lucchinetti CF
    J Neuroimmunol; 2005 Dec; 169(1-2):137-43. PubMed ID: 16182378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of kinin receptors on eosinophils: comparison of asthmatic patients and healthy subjects.
    Bertram CM; Misso NL; Fogel-Petrovic M; Figueroa CD; Foster PS; Thompson PJ; Bhoola KD
    J Leukoc Biol; 2009 Mar; 85(3):544-52. PubMed ID: 19038786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of nuclear factor-kappaB and protein kinase C signaling in the expression of the kinin B1 receptor in human vascular smooth muscle cells.
    Moreau ME; Bawolak MT; Morissette G; Adam A; Marceau F
    Mol Pharmacol; 2007 Mar; 71(3):949-56. PubMed ID: 17178924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Use of magnetic resonance imaging in the diagnosis and prognosis of multiple sclerosis].
    Zivadinov R; Sepcić J
    Lijec Vjesn; 2006; 128(9-10):295-308. PubMed ID: 17128669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Motor evoked potential: a reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI.
    Kalkers NF; Strijers RL; Jasperse MM; Neacsu V; Geurts JJ; Barkhof F; Polman CH; Stam CJ
    Clin Neurophysiol; 2007 Jun; 118(6):1332-40. PubMed ID: 17398151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis.
    Amato MP; Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; De Stefano N
    Neurology; 2008 Aug; 71(9):632-8. PubMed ID: 18725589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS.
    Eikelenboom MJ; Killestein J; Izeboud T; Kalkers NF; Baars PA; van Lier RA; Barkhof F; Uitdehaag BM; Polman CH
    J Neuroimmunol; 2005 Jan; 158(1-2):222-30. PubMed ID: 15589057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study.
    Rudick RA; Lee JC; Simon J; Fisher E
    Ann Neurol; 2006 Aug; 60(2):236-42. PubMed ID: 16786526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity.
    Wiendl H; Feger U; Mittelbronn M; Jack C; Schreiner B; Stadelmann C; Antel J; Brueck W; Meyermann R; Bar-Or A; Kieseier BC; Weller M
    Brain; 2005 Nov; 128(Pt 11):2689-704. PubMed ID: 16123145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ADC measurements in various patterns of multiple sclerosis lesions.
    Phuttharak W; Galassi W; Laopaiboon V; Laopaiboon M; Hesselink JR
    J Med Assoc Thai; 2006 Feb; 89(2):196-204. PubMed ID: 16579006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Decrease of FOXP3 mRNA in CD4+ T cells in latent autoimmune diabetes in adult].
    Yang ZF; Zhou ZG; Tang WL; Huang G; Peng J; Li X; He L
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(36):2533-6. PubMed ID: 17198560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
    Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z
    Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression of kinin receptors B1 and B2 in PBMC from patients with cardiac syndrome X.
    Dabek J; Wilczok T; Gasior Z; Kucia-Kuzma S; Twardowski R; Kulach A
    Scand Cardiovasc J; 2007 Dec; 41(6):391-6. PubMed ID: 17852785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis.
    Chowdhury SA; Lin J; Sadiq SA
    Arch Neurol; 2008 Feb; 65(2):232-5. PubMed ID: 18268193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis.
    Pascual AM; Martínez-Bisbal MC; Boscá I; Valero C; Coret F; Martínez-Granados B; Marti-Bonmati L; Mir A; Celda B; Casanova B
    Neurology; 2007 Jul; 69(1):63-7. PubMed ID: 17606882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
    Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
    Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.